Failure of thrombin inhibition to prevent intracoronary thrombosis in the dog

Clinical Science

Volumn 90, Issue 5, 1996, Pages 363-368

  Belcher, Philip R ^b   Drake Holland, Angela J ^a   Hynd, John W ^a   Noble, Mark I M ^a  

^a CHARING CROSS HOSPITAL   (United Kingdom)

^b GLASGOW ROYAL INFIRMARY   (United Kingdom)

Author keywords

Artery; Blood; Coagulation; Coronary; Platelets

Indexed keywords

LEPIRUDIN; THROMBIN; THROMBIN INHIBITOR; THROMBIN RECEPTOR; THROMBOCYTE RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLEEDING TIME; BLOOD CLOTTING; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY OBSTRUCTION; CORONARY ARTERY THROMBOSIS; DOG; HEART HEMODYNAMICS; HEART RATE; INTRAVENOUS DRUG ADMINISTRATION; MEAN ARTERIAL PRESSURE; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; SHEAR RATE; THROMBIN TIME; THROMBOSIS;

EID: 0029875007     PISSN: 01435221     EISSN: None     Source Type: Journal    
DOI: 10.1042/cs0900363     Document Type: Article

References (37)

1. Folts J, Crowell E, Rowe G. Platelet aggregation in partially obstructed vessels and its elimination with aspirin. Circulation 1976; 54: 365-70.
2. Folts JD, Gallagher K, Rowe GG. Blood flow reductions in stenosed canine coronary arteries: vasospasm or platelet aggregation. Circulation 1982; 65: 248-55.
3. Eidt J, Allison P, Noble S, et al. Thrombin is an important mediator of platelet aggregation in stenosed canine coronary arteries with endothelial injury. J Clin Invest 1989; 84: 18-27.
4. Haerem J. Platelet aggregates in intramyocardial vessels of patients dying suddenly and unexpectedly of coronary artery disease. Atherosclerosis 1972; 15: 199-213.
5. Chesebro J, Zoldhelyi P, Fuster V. Pathogenesis of thrombosis in unstable angina. Am J Cardiol 1991; 68: 2-10B.
6. Faivre R, Soria C, Sonia J, Mirshahi M, Caen J. Prevention of coronary reocclusion after rt-PA-induced thrombolysis: in vitro effects of r-Hirudin (Abstract). Arterioscler Thromb 1991; 11: 1567A.
7. Belcher PR, Drake-Holland AJ, Hynd JW, Noble MIM. Dispersion of coronary artery thrombi by antagonism of platelet serotonin receptor in the dog. Cardiovasc Res 1992; 24: 292-6.
8. McAuliffe S, Snow H, Cox B, Smith C, Noble M. Interaction between the effects of 5-hydroxytryptamine and adrenaline on the growth of platelet thrombi in the coronary artery of the anaesthetised dog. Br J Pharmacol 1993; 109: 405-10.
9. 2 receptor antagonist ritanserin. Cardiovasc Res 1990; 24: 465-70.
10. Antman EM, for the TIMI 9a investigators. Hirudin in acute myocardial infarction. Safety report from the thrombolysis and thrombin inhibition in myocardial infarction (TIMI) 9a trial. Circulation 1994; 90: 1624-30.
11. The global use of strategies to open coronary arteries (GUSTO) IIa investigators. Randomized trial of intravenous heparin versus recombinant hirudin for acute myocardial infarction. Circulation 1994; 90: 1631-7.
12. Neuhaus K-L, Essen Rv, Tebbe U, et al. Safety observations from the pilot phase of the randomized r-hirudin for improvement of thrombolysis (HIT-III) study. Circulation 1994; 90: 1638-42.
13. Jergens A, Turrentine M, Kraus K, Johnson G. Buccal mucosa bleeding times of healthy dogs and of dogs in various pathologic states, including thrombocytopenia, uremia, and von Willebrand's disease. Am J Vet Res 1987; 48: 1337-42.
14. Cercek B, Lew A, Hod H, Yano J, Reddy N, Ganz W. Enhancement of thrombolysis with tissue-type plasminogen activator by pretreatment with heparin. Circulation 1986; 74: 583-7.
15. Gruppo Italiano per lo Studio della Sopravivenza nell'Infarcto Miocardico: (GISSI-2). A factorial randomized trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction. Lancet 1990; 336: 65-71.
16. Hanson S, Harker L. Interruption of acute platelet-dependent thrombosis by the synthetic antithrombin D-phenylalanyl-L-propyl-L-arginyl chloromethyl ketone. Proc Natl Acad Sci USA 1988; 85: 3184-8.
17. Weitz J, Hudoba M, Massel D, Maraganore J, Hirsh J. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest 1990; 86: 385-91.
18. Hsia J, Kleiman N, Aguirre F, Chaitman B, Roberts R, Ross AM. Heparin-induced prolongation of partial thromboplastin time after thrombolysis: relation to coronary artery patency. J Am Coll Cardiol 1992; 20: 31-5.
19. Chesebro J, Fuster V. Reperfusion, specific thrombin inhibition and reocclusion after thrombolysis (editorial). J Am Coll Cardiol 1990; 14: 723-5.
20. Eichhorn E, Grayburn P, Willard J, et al. Spontaneous alterations in coronary blood flow velocity before and after coronary angioplasty in patients with severe angina. J Am Coll Cardiol 1991; 17: 43-52.
21. Mustard J, Packham M, Kinlough-Rathbone R. Platelets, blood flow, and the vessel wall. Circulation 1990; 81 (Suppl. 1): 24-7.
22. Rudd M, George D, Johnstone M, et al. Effect of thrombin inhibition on the dynamics of thrombolysis and on platelet function during thrombolytic therapy. Circ Res 1992; 70: 829-34.
23. Walenga J, Bakhos M, Messmore H, Fareed J, Pifarre R. Potential use of recombinant hirudin as an anticoagulant in a cardiopulmonary bypass model. Ann Thorac Surg 1991; 51: 271-7.
24. Hung D, Vu T, Wheaton V, Ishii K, Coughlin S. Cloned platelet thrombin receptor is necessary for thrombin-induced platelet activation. J Clin Invest 1992; 89: 1350-3.
25. Sitko G, Ramjit D, Stabilito I, Lehman D, Lynch J, Vlasuk G. Conjunctive enhancement of enzymatic thrombolysis and prevention of thrombotic reocclusion with the selective factor Xa inhibitor, tick anticoagulant peptide. Circulation 1992; 85: 805-15.
26. Yao S-K, McNatt J, Anderson V, et al. Thrombin inhibition enhances tissue-type plasminogen activator-induced thrombolysis and delays reocclusion. Am J Physiol 1992; 262: H374-9.
27. 2 receptor activation of cyclic flow variations in dogs with severe coronary artery stenoses. Circulation 1987; 76: 952-9.
28. 2 receptor antagonist, of the formation of coronary thrombi in dogs. Cardiovasc Res 1991; 25: 727-30.
29. Belcher PR, Drake-Holland AJ, Hynd JW, Noble MIM. Effects of trimetazidine on in vivo coronary arterial platelet thrombosis. Cardiovasc Drugs Ther 1993; 7: 140-57.
30. Winn M, Jain K, Ku D. Argatroban and inhibition of the vasomotor actions of thrombin. J Cardiovasc Pharmacol 1993; 12: 754-40.
31. Yasuda T, Gold H, Yaoita H, et al. Comparative effects of aspirin, a synthetic thrombin inhibitor and a monoclonal antiplatelet glycoprotein IIb/IIIa antibody on coronary artery reperfusion, reocclusion and bleeding with recombinant tissue-type plasminogen activator in a canine preparation. J Am Coll Cardiol 1990; 16: 714-22.
32. Reilly T, Knabb R, Hassell S, et al. Effect of thrombin inhibitors on platelet functions: comparative analysis of DuP714 and hirudin. Blood Coagulation Fibrinolysis 1992; 3: 513-17.
33. Evangelista V, Piccandoni P, Manjeri N, de Gaetano G, Cerletti C. Inhibition by heparin of platelet activation induced by neutrophil-derived cathepsin G. Eur J Pharmacol 1992; 216: 401-5.
34. Merlini P, Bauer K, Oltrona L, et al. Persistent activation of coagulation mechanism in unstable angina and myocardial infarction. Circulation 1994; 90: 61-8.
35. Catto A, Carter A, Ireland H, et al. Factor V Leiden gene mutation and thrombin generation in relation to the development of acute stroke. Arterioscler Thromb 1995; 15: 783-5.
36. Bockxmeer Fv, Baker R, Taylor R. Premature ischaemic heart disease and the gene for coagulation factor V. Nature Med 1995; 1: 185.
37. Emmerich J, Poirier O, Evans A, et al. Myocardial infarction, Arg 504 to Gin factor V mutation, and activated protein C resistance. Lancet 1995; 345: 321.